More articles from Current Drug Therapy

  • Update on hormonal contraception
    Nziavake Masimasi, MD, Mala S. Sivanandy, MD and Holly L. Thacker, MD
    Cleveland Clinic Journal of Medicine March 2007, 74 (3) 186-198;

    The trends are for lower estrogen doses, newer progestins, longer cycles, and non-oral options. A review of the latest products.

  • Glucosamine in osteoarthritis: Questions remain
    Carlos J. Lozada, MD
    Cleveland Clinic Journal of Medicine January 2007, 74 (1) 65-71;

    Glucosamine is now widely used, but studies have so far failed to prove convincingly that it works, how it might work, or whether it is safe to take long-term.

  • The controversy over long-acting beta agonists: Examining the evidence
    David M. Lang, MD
    Cleveland Clinic Journal of Medicine November 2006, 73 (11) 973-992;

    Asthma drugs that contain salmeterol (Serevent, Advair) or formoterol (Foradil) now carry a warning about an increased risk of asthma-related death. This paper critically examines the evidence.

  • Using the new HPV vaccines in clinical practice
    Lea E. Widdice, MD and Jessica A. Kahn, MD, MPH
    Cleveland Clinic Journal of Medicine October 2006, 73 (10) 929-935;

    The new vaccines against human papillomavirus (HPV) could prevent up to 70% of cases of cervical cancer. But Pap testing will still be necessary.

  • Newer antibiotics for serious gram-positive infections
    Thomas G. Fraser, MD, Christine Hansen, PharmD and Jennifer K. Long, PharmD
    Cleveland Clinic Journal of Medicine September 2006, 73 (9) 847-853;

    We use two case scenarios to discuss when and how to use these agents and how to monitor and respond to their adverse effects.

  • Is digoxin a drug of the past?
    Is digoxin a drug of the past?
    Mohammad Hassan Pervaiz, MD, Michael G. Dickinson, MD and Mohamad Yamani, MD
    Cleveland Clinic Journal of Medicine September 2006, 73 (9) 821-834;

    This old drug is still useful, with some caveats. It is no longer the cornerstone of heart-failure treatment, but it can be beneficial as an adjunct. Serum levels should probably be kept lower than in the past.

  • Drug adjuncts for treating alcohol dependence
    Gregory B. Collins, MD, Mark S. McAllister, MD and Kamala Adury, MD
    Cleveland Clinic Journal of Medicine July 2006, 73 (7) 641-656;

    We have learned much about the neurochemical basis of alcohol dependence over the past 20 years, but we still have only a few drugs for treating it. We need better ones.

  • Inhaled human insulin: An inspiration for patients with diabetes mellitus?
    Inhaled human insulin: An inspiration for patients with diabetes mellitus?
    Michael B. Davidson, DO, Adi E. Mehta, MD and Elias S. Siraj, MD
    Cleveland Clinic Journal of Medicine June 2006, 73 (6) 569-578;

    We discuss the pharmacology, efficacy, important clinical trials, and practical aspects of inhaled insulin, and potential concerns associated with its use.

  • Exenatide and pramlintide: New glucose-lowering agents for treating diabetes mellitus
    Byron J. Hoogwerf, MD
    Cleveland Clinic Journal of Medicine May 2006, 73 (5) 477-484;

    Insulin is not the only hormone that regulates plasma glucose levels. Two new drugs based on native hormones became available in 2005.

  • New therapies for type 2 diabetes based on glucagon-like peptide 1
    Marzieh Salehi, MD and David A. D’alessio, MD
    Cleveland Clinic Journal of Medicine April 2006, 73 (4) 382-389;

    Several new agents are under development, and one has been approved. They will be attractive for a number of reasons.

Pages